Acerta Pharma Bv

This early-phase study tests a new drug combination (acalabrutinib plus ceralasertib) in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatments. The main goal is to check safety and find the right dose. Participants must…

This phase 3 study compares two oral targeted therapies, acalabrutinib and ibrutinib, in 533 adults with high-risk chronic lymphocytic leukemia (CLL) who have already received at least one prior treatment. The main goal is to see if acalabrutinib is as good as or better than ibru…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer worsening. About 635 adults aged 65 and older took part. The goal is to see if t…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a certain type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). About 611 adults aged 18 to 75 with stage II to IV disease are participating. The main go…

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…

This study tests a new drug called acalabrutinib combined with standard treatments (bendamustine and rituximab, or venetoclax and rituximab) in people with untreated mantle cell lymphoma, a rare blood cancer. The main goal is to check safety and side effects. About 72 adults will…

This study tested a new drug called acalabrutinib in 306 adults with chronic lymphocytic leukemia (CLL) or related blood cancers that had not responded to at least two prior treatments. The goal was to check the drug's safety and how well it works. Acalabrutinib is a targeted the…

This study tested a drug called acalabrutinib (ACP-196) in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the drug could shrink tumors and improve symptoms. Participants took the drug daily, and researchers measured how many people resp…

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib because of side effects. The goal is to see if ACP-196 can shrink or control the cancer. …

This study tests a drug called acalabrutinib, given alone or with other medicines, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the drug is safe and can shrink tumors. About 113 adults took part. This is…

This study tests a drug called ACP-196 (acalabrutinib) in 24 adults whose glioblastoma brain cancer has returned after standard treatment. The goal is to see if the drug can shrink or control the tumor. Participants take the drug by mouth, and doctors monitor their response using…

This study tested a new drug called acalabrutinib against two standard combination therapies for adults with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to previous treatment. About 310 participants received either acalabrutinib alone or a standard…